Despite encouraging clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant opposition from pharmacy benefit managers. These companies are https://murraypjjj935100.estate-blog.com/40812758/company-s-vyndamax-faces-is-encountering-pharmacy-benefit-manager-challenges-a-look-at-reimbursement-disputes